Abstract
Apatinib, an inhibitor of vascular endothelial growth factor receptor-2 with potent anti-angiogenic activity, has shown promising anticancer activity in various solid tumors. For patients with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) who have previously received standard chemotherapy or radiotherapy, there are few effective treatment options. We conducted a single-arm, multi-center, phase II trial to evaluate the efficacy and safety of apatinib for the treatment of R/M HNSCC patients who failed from one or more lines of therapies.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
